Facile Production of the Pseudomonas aeruginosa Virulence Factor LasB in Escherichia coli for Structure-Based Drug Design

The human pathogen Pseudomonas aeruginosa has a number of virulence factors at its disposal that play crucial roles in the progression of infection. LasB is one of the major virulence factors and exerts its effects through elastolytic and proteolytic activities aimed at dissolving connective tissue and inactivating host defense proteins. LasB is of great interest for the development of novel pathoblockers to temper the virulence, but access has thus far largely been limited to protein isolated from Pseudomonas cultures. Here, we describe a new protocol for high-level production of native LasB in Escherichia coli. We demonstrate that this facile approach is suitable for the production of mutant, thus far inaccessible LasB variants, and characterize the proteins biochemically and structurally. We expect that easy access to LasB will accelerate the development of inhibitors for this important virulence factor.

Automated summary

The human pathogen Pseudomonas aeruginosa possesses various virulence factors that are crucial in infection progression. LasB, a major virulence factor, plays a role in dissolving connective tissue and deactivating host defense proteins. In this study, we present a new protocol for high-level production of native LasB in Escherichia coli, allowing for easier access to LasB and acceleration in the development of inhibitors targeting this important virulence factor.